Monte Rosa Therapeutics (GLUE)
Market Price (7/10/2026): $24.99 | Market Cap: $2.5 BilSector: Health Care | Industry: Biotechnology
Monte Rosa Therapeutics (GLUE)
Market Price (7/10/2026): $24.99Market Cap: $2.5 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. | Trading close to highsDist 52W High is -3.1%, Dist 3Y High is -3.1% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -148 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -345% Stock price has recently run up significantly12M Rtn12 month market price return is 364% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -73%, Rev Chg QQuarterly Revenue Change % is -95% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 45% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -34%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -46% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 426% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.5% Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 16.62 Key risksGLUE key risks include [1] reliance on its novel molecular glue degrader (MGD) platform which is largely unproven in humans, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Trading close to highsDist 52W High is -3.1%, Dist 3Y High is -3.1% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 17% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -148 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -345% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 364% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -73%, Rev Chg QQuarterly Revenue Change % is -95% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 45% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -34%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -46% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 426% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -9.5% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 16.62 |
| Key risksGLUE key risks include [1] reliance on its novel molecular glue degrader (MGD) platform which is largely unproven in humans, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Monte Rosa Therapeutics (GLUE) stock has gained about 50% since 3/31/2026 because of the following key factors:
1. Advancement of Multiple Clinical Programs and Positive Data. Monte Rosa Therapeutics reported positive interim Phase 1 clinical data for MRT-8102 in January 2026 (prior to the current period, but reiterated in Q1 2026 business updates), demonstrating an 85% reduction in C-reactive protein (CRP) levels in subjects with elevated cardiovascular disease (CVD) risk, with 94% of participants achieving CRP levels below 2 mg/L. Furthermore, in the first fiscal quarter ended March 31, 2026, the company announced that all three of its clinical-stage programs—MRT-8102, MRT-2359 (for metastatic castration-resistant prostate cancer), and MRT-6160—are approaching Phase 2 trial initiations, with multiple Phase 2 studies for MRT-8102 anticipated to begin in the second half of 2026 (H2 2026) and a Phase 2 study for MRT-2359 planned for fiscal Q3 2026. Additionally, in April 2026, the company presented positive preclinical data for its cyclin E1 (CCNE1)-directed molecular glue degrader, MRT-55811, at the AACR Annual Meeting, showing tumor regressions in CCNE1-amplified solid tumor models and anticipating an IND submission in H2 2026.
2. Robust Financial Position and Extended Cash Runway. As of March 31, 2026, Monte Rosa Therapeutics maintained a strong balance sheet with $671 million in cash, cash equivalents, restricted cash, and marketable securities, which is projected to fund its operations into 2029. This substantial cash runway provides significant financial stability, reducing concerns about near-term dilution and enabling continued investment in its clinical pipeline.
Show more
Monte Rosa Therapeutics (GLUE) stock has gained about 50% since 3/31/2026 because of the following key factors:
1. Advancement of Multiple Clinical Programs and Positive Data. Monte Rosa Therapeutics reported positive interim Phase 1 clinical data for MRT-8102 in January 2026 (prior to the current period, but reiterated in Q1 2026 business updates), demonstrating an 85% reduction in C-reactive protein (CRP) levels in subjects with elevated cardiovascular disease (CVD) risk, with 94% of participants achieving CRP levels below 2 mg/L. Furthermore, in the first fiscal quarter ended March 31, 2026, the company announced that all three of its clinical-stage programs—MRT-8102, MRT-2359 (for metastatic castration-resistant prostate cancer), and MRT-6160—are approaching Phase 2 trial initiations, with multiple Phase 2 studies for MRT-8102 anticipated to begin in the second half of 2026 (H2 2026) and a Phase 2 study for MRT-2359 planned for fiscal Q3 2026. Additionally, in April 2026, the company presented positive preclinical data for its cyclin E1 (CCNE1)-directed molecular glue degrader, MRT-55811, at the AACR Annual Meeting, showing tumor regressions in CCNE1-amplified solid tumor models and anticipating an IND submission in H2 2026.
2. Robust Financial Position and Extended Cash Runway. As of March 31, 2026, Monte Rosa Therapeutics maintained a strong balance sheet with $671 million in cash, cash equivalents, restricted cash, and marketable securities, which is projected to fund its operations into 2029. This substantial cash runway provides significant financial stability, reducing concerns about near-term dilution and enabling continued investment in its clinical pipeline.
3. Significant Potential from Novartis Collaboration Milestones. Monte Rosa Therapeutics' collaboration with Novartis holds substantial future value, with the company eligible to receive up to $2.1 billion in development, regulatory, and sales milestones. These milestone payments are set to commence upon the initiation of Phase 2 studies, including those for the VAV1-directed MGD MRT-6160, which Novartis is expected to initiate in immune-mediated diseases in 2026.
4. Inclusion in Russell Growth Indexes. The company's inclusion in several Russell growth benchmarks on June 27, 2026, following a reshuffle of Russell indexes, contributed to positive stock momentum. Such inclusions often lead to increased buying activity from institutional investors and passive index funds, providing broader market exposure and investor confidence.
Show less
Stock Movement Drivers
Fundamental Drivers
The 49.1% change in GLUE stock from 3/31/2026 to 7/9/2026 was primarily driven by a 401.1% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7092026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.45 | 24.52 | 49.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 124 | 43 | -65.3% |
| P/S Multiple | 11.4 | 57.0 | 401.1% |
| Shares Outstanding (Mil) | 86 | 100 | -14.4% |
| Cumulative Contribution | 49.1% |
Market Drivers
3/31/2026 to 7/9/2026| Return | Correlation | |
|---|---|---|
| GLUE | 49.1% | |
| Market (SPY) | 15.6% | 18.5% |
| Sector (XLV) | 10.6% | 15.1% |
Fundamental Drivers
The 56.4% change in GLUE stock from 12/31/2025 to 7/9/2026 was primarily driven by a 701.2% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7092026 | Change |
|---|---|---|---|
| Stock Price ($) | 15.68 | 24.52 | 56.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 182 | 43 | -76.3% |
| P/S Multiple | 7.1 | 57.0 | 701.2% |
| Shares Outstanding (Mil) | 82 | 100 | -17.5% |
| Cumulative Contribution | 56.4% |
Market Drivers
12/31/2025 to 7/9/2026| Return | Correlation | |
|---|---|---|
| GLUE | 56.4% | |
| Market (SPY) | 10.5% | 11.7% |
| Sector (XLV) | 5.2% | 19.7% |
Fundamental Drivers
The 443.7% change in GLUE stock from 6/30/2025 to 7/9/2026 was primarily driven by a 2354.5% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7092026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.51 | 24.52 | 443.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 159 | 43 | -73.1% |
| P/S Multiple | 2.3 | 57.0 | 2354.5% |
| Shares Outstanding (Mil) | 82 | 100 | -17.8% |
| Cumulative Contribution | 443.7% |
Market Drivers
6/30/2025 to 7/9/2026| Return | Correlation | |
|---|---|---|
| GLUE | 443.7% | |
| Market (SPY) | 22.7% | 15.5% |
| Sector (XLV) | 21.9% | 14.4% |
Fundamental Drivers
The 258.0% change in GLUE stock from 6/30/2023 to 7/9/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302023 | 7092026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.85 | 24.52 | 258.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 43 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 57.0 | |
| Shares Outstanding (Mil) | 49 | 100 | -50.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
6/30/2023 to 7/9/2026| Return | Correlation | |
|---|---|---|
| GLUE | 258.0% | |
| Market (SPY) | 75.6% | 20.1% |
| Sector (XLV) | 27.9% | 17.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GLUE Return | -4% | -63% | -26% | 23% | 126% | 53% | 14% |
| Peers Return | -3% | -49% | -3% | 13% | 2% | 35% | -24% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| GLUE Win Rate | 71% | 33% | 33% | 50% | 50% | 57% | |
| Peers Win Rate | 52% | 43% | 35% | 48% | 55% | 51% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| GLUE Max Drawdown | - | -70% | -70% | -60% | -48% | -42% | |
| Peers Max Drawdown | -44% | -63% | -64% | -45% | -57% | -29% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: KYMR, NRIX, ARVN, CCCC, BMY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/9/2026 (YTD)
How Low Can It Go
| Event | GLUE | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -44.2% | -18.8% |
| % Gain to Breakeven | 79.2% | 23.1% |
| Time to Breakeven | 124 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -62.7% | -9.5% |
| % Gain to Breakeven | 168.0% | 10.5% |
| Time to Breakeven | 76 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -31.3% | -6.7% |
| % Gain to Breakeven | 45.5% | 7.1% |
| Time to Breakeven | 34 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.9% | -24.5% |
| % Gain to Breakeven | 231.9% | 32.4% |
| Time to Breakeven | 1301 days | 427 days |
In The Past
Monte Rosa Therapeutics's stock fell -44.2% during the 2025 US Tariff Shock. Such a loss loss requires a 79.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | GLUE | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -44.2% | -18.8% |
| % Gain to Breakeven | 79.2% | 23.1% |
| Time to Breakeven | 124 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -62.7% | -9.5% |
| % Gain to Breakeven | 168.0% | 10.5% |
| Time to Breakeven | 76 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -31.3% | -6.7% |
| % Gain to Breakeven | 45.5% | 7.1% |
| Time to Breakeven | 34 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.9% | -24.5% |
| % Gain to Breakeven | 231.9% | 32.4% |
| Time to Breakeven | 1301 days | 427 days |
In The Past
Monte Rosa Therapeutics's stock fell -44.2% during the 2025 US Tariff Shock. Such a loss loss requires a 79.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE) is a biopharmaceutical company at the forefront of developing a novel class of precision medicines called "molecular glue degraders." These innovative small molecule drugs are designed to harness the body's natural protein degradation mechanisms to selectively eliminate specific disease-causing proteins. This approach seeks to provide highly targeted and effective treatments across a spectrum of difficult-to-treat diseases.
The company's pipeline includes several key programs. Its lead candidate is an oral molecular glue degrader targeting GSPT1, specifically developed for the treatment of Myc-driven cancers. In oncology, Monte Rosa is also advancing a program for CDK2, aimed at addressing ovarian, uterine, and breast cancers. Beyond cancer, the company is developing NEK7 for inflammatory diseases such as Crohn's disease, neurodegenerative conditions, diabetes, and liver disease.
Monte Rosa Therapeutics further expands its therapeutic focus with programs targeting VAV1 for autoimmune diseases and BCL11A for hemoglobinopathies. By leveraging its molecular glue degrader platform, Monte Rosa aims to serve patients in need of advanced treatments for a wide range of cancers, inflammatory and autoimmune disorders, and genetic blood diseases.
AI Analysis | Feedback
- Genentech for targeted protein degradation.
- Moderna for protein 'clean-up' drugs.
AI Analysis | Feedback
- Oral molecular glue degrader for GSPT1: A precision medicine for the treatment of Myc-driven cancers.
- CDK2: A treatment in development for ovarian, uterine, and breast cancers.
- NEK7: A therapeutic target for inflammatory diseases, including Crohn's disease, neurodegenerative disease, diabetes, and liver disease.
- VAV1: A target protein being developed for autoimmune diseases.
- BCL11A: A therapeutically-relevant protein targeted for hemoglobinopathies.
AI Analysis | Feedback
Monte Rosa Therapeutics, Inc. (GLUE) is a clinical-stage biopharmaceutical company focused on the research and development of novel small molecule precision medicines. As of now, the company does not have any commercialized products on the market.
Therefore, Monte Rosa Therapeutics does not currently have major customers that purchase its products. Its primary activities are advancing its pipeline candidates through preclinical and clinical development.
AI Analysis | Feedback
AI Analysis | Feedback
Markus Warmuth, M.D., Chief Executive Officer
Dr. Warmuth has served as President and Chief Executive Officer of Monte Rosa Therapeutics since January 2020. He brings over 20 years of experience in drug discovery and precision medicine. Prior to Monte Rosa, he was an Entrepreneur-in-Residence at Third Rock Ventures, where he was involved in forming new biotech companies. He also served as Chief Executive Officer of H3 Biomedicine for seven years, an oncology biopharmaceutical company, leading teams involved in developing Ceritinib and Ribociclib. Dr. Warmuth also held multiple leadership roles at the Novartis Institutes for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), contributing to the development of Ceritinib and Ribociclib, and the discovery of allosteric SHP2 and Abl inhibitors. He currently serves as a Venture Partner at Versant Ventures.
Ajim Tamboli, CFA, Chief Financial Officer
Mr. Tamboli has served as Chief Financial Officer of Monte Rosa Therapeutics since September 2020. He was instrumental in leading private and public fundraises exceeding $465 million for Monte Rosa, including an upsized $255 million IPO. Before joining Monte Rosa, Mr. Tamboli was CFO at Rodin Therapeutics, where he managed investor fundraising and supported its acquisition by Alkermes for up to $950 million. He also previously served as a founding partner of Endurant Capital Management, a healthcare-dedicated asset management firm, and worked with Columbia Management, focusing on life sciences investing and managing a global portfolio of biotech and pharmaceutical companies. Earlier in his career, he led coverage and executed IPOs and follow-on offerings for numerous biotech and healthcare companies at Lehman Brothers, Credit Suisse, and Lazard Frères.
Sharon Townson, Ph.D., Chief Scientific Officer
Dr. Townson was promoted to Chief Scientific Officer on May 30, 2024, after joining Monte Rosa as Chief Technology Officer. She brings extensive expertise in molecular glues and targeted protein degradation technology platforms. Prior to Monte Rosa, she served as Executive Director of Platform Biology at Kymera Therapeutics. Dr. Townson was also part of the leadership team at Warp Drive Bio, where she was responsible for developing a novel molecular glue approach targeting KRAS. She began her career at Pfizer as a structural biologist.
Jennifer Champoux, Chief Operating Officer
Ms. Champoux was promoted to Chief Operating Officer on May 30, 2024. She previously held the roles of Chief People and Operations Officer since March 2023 and Senior Vice President of Operations from March 2021 to March 2023 at Monte Rosa. Before joining the company, Ms. Champoux was Executive Director of Operations at H3 Biomedicine, leading operations, communications, and finance operations teams. She also led operations for the Discovery Chemistry group at Novartis Institutes for Biomedical Research in Cambridge. Her career began in various pharmaceutical development functions at Merck and Array BioPharma.
Phil Nickson, Ph.D., J.D., Chief Business and Legal Officer
Dr. Nickson was promoted to Chief Business and Legal Officer on May 30, 2024, having joined Monte Rosa in 2021 as General Counsel to support the company's IPO. In his role, he leads Monte Rosa's business development and legal departments. Prior to Monte Rosa, he spent over 10 years with Momenta Pharmaceuticals until its acquisition by Johnson and Johnson in 2020, and then supported the integration of Momenta into J&J for approximately one year.
AI Analysis | Feedback
Key Risks to Monte Rosa Therapeutics (GLUE)
- Clinical Trial Success and Development Risk: As an early-stage biopharmaceutical company, Monte Rosa Therapeutics' business heavily relies on the successful development and clinical validation of its novel small molecule precision medicines. The inherent failure rates in clinical trials are high, and the success of its drug candidates, currently in Phase 1 and progressing to Phase 2, is the primary and highest-impact catalyst for the company. Biopharmaceutical drug development is a highly speculative undertaking with a substantial degree of risk.
- Funding, Cash Burn, and Shareholder Dilution Risk: Developing new drugs is an expensive and capital-intensive process. Monte Rosa Therapeutics has a significant cash burn and, as an early-stage biotech, will likely require future financing, which poses a substantial risk of dilution for existing shareholders. Despite a current cash runway expected to last into 2028, recent equity raises have already highlighted concerns about potential dilution. The company has also experienced unstable profits and declining revenue forecasts.
- Regulatory Approval and Unproven Technology Risk: Even with successful clinical trials, obtaining regulatory approval (e.g., from the FDA) for its drug candidates is not guaranteed and can be unpredictable, potentially hindering market entry and future opportunities. Furthermore, Monte Rosa's core molecular glue degrader technology, while innovative and promising, is still largely unproven in its broader application and commercialization, introducing an additional layer of uncertainty regarding its long-term viability and competitive standing.
AI Analysis | Feedback
AI Analysis | Feedback
- Oral molecular glue degrader for GSPT1 (Myc-driven cancers): The global Myc proto-oncogene protein market was valued at USD 1.68 billion in 2024 and is projected to grow to USD 3.06 billion by 2029. The GSPT1 segment of the global molecular glue degrader market was estimated at approximately USD 74.3 million in 2024.
-
CDK2 inhibitor (Ovarian, Uterine, and Breast Cancers):
- Ovarian Cancer: The global ovarian cancer treatment market size was estimated at USD 3.5 billion in 2023, with projections to reach approximately USD 6.5 billion by 2032. The global ovarian cancer drugs market size was USD 4.09 billion in 2025 and is projected to hit around USD 7.78 billion by 2035.
- Uterine Cancer: The global uterine cancer treatment market size was approximately USD 23,633.46 million (USD 23.63 billion) in 2024 and is expected to reach nearly USD 39,007.22 million (USD 39.01 billion) by 2033.
- Breast Cancer: The global breast cancer market size was estimated at USD 26.23 billion in 2025 and is predicted to increase to approximately USD 40.11 billion by 2035.
-
NEK7 inhibitor (Inflammatory Diseases, such as Crohn's disease, Neurodegenerative disease, Diabetes, and Liver disease):
- Crohn's Disease: The global Crohn's Disease Market was estimated at USD 11.93 billion in 2024 and is projected to grow to USD 17.83 billion by 2035.
- Neurodegenerative Disease: The global neurodegenerative disease market size is estimated to be valued at USD 55.6 billion in 2025 and is projected to reach USD 109.5 billion by 2035.
- Diabetes: The global diabetes drugs market size was valued at USD 101.48 billion in 2025 and is projected to grow to USD 283.36 billion by 2034.
- Liver Disease: A specific addressable market size for "inflammatory liver disease" was not identified in the provided search results.
- VAV1 (Autoimmune Diseases): The global autoimmune disease therapeutics market is valued at USD 168.6 billion in 2025 and is forecast to reach USD 226.2 billion by 2035.
- BCL11A (Hemoglobinopathies): The global hemoglobinopathies market size is valued at USD 5.12 billion in 2025 and is predicted to increase to approximately USD 8.87 billion by 2035.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Monte Rosa Therapeutics (GLUE) over the next 2-3 years:
- Milestone Payments from Novartis Collaboration for MRT-6160: Monte Rosa Therapeutics is eligible to receive significant development, regulatory, and sales milestones, potentially up to $2.1 billion, from its collaboration with Novartis for the VAV1-directed molecular glue degrader (MGD) MRT-6160. These payments are expected to begin upon the initiation of Phase 2 studies, which Novartis is anticipated to commence for MRT-6160 in immune-mediated diseases in 2026.
- Advancement of MRT-2359 into Phase 2 Studies: The company plans to initiate a Phase 2 study in the third quarter of 2026 for MRT-2359, its GSPT1 degrader, in combination with apalutamide for metastatic castration-resistant prostate cancer (mCRPC). This progression into a later-stage clinical trial, following encouraging Phase 1/2 data, is a key clinical catalyst that could drive future revenue.
- Progression of MRT-8102 into Phase 2 Studies: Monte Rosa Therapeutics expects to share data from its GFORCE-1 study of MRT-8102, a NEK7-directed MGD for inflammatory diseases, in the second half of 2026. This is expected to lead to the initiation of the Phase 2 GFORCE-2 study in atherosclerotic cardiovascular disease (ASCVD) in 2026. Positive interim Phase 1 data showing robust activity and reduction in inflammatory markers supports this advancement.
- Initiation of New Clinical Programs from the QuEEN™ Discovery Engine: Leveraging its proprietary QuEEN™ AI/ML-powered discovery engine, Monte Rosa Therapeutics anticipates submitting an Investigational New Drug (IND) application in 2026 for a CDK2 and/or cyclin E1-directed MGD. This would introduce a new oncology program into clinical development, expanding the company's pipeline and future revenue potential.
AI Analysis | Feedback
Share Issuance
- Monte Rosa Therapeutics completed its Initial Public Offering (IPO) on June 24, 2021, issuing 11,700,000 shares of common stock at $19.00 per share and receiving net proceeds of $203.9 million after deducting underwriting discounts and offering costs.
- The company terminated its at-the-market (ATM) equity program prospectus on January 7, 2026, after raising $24.2 million through this program.
- The number of outstanding shares for Monte Rosa Therapeutics increased by 22.34% in the year prior to March 2026.
Inbound Investments
- Monte Rosa Therapeutics reported collaboration revenue of $12.8 million in Q3 2025, up from $9.2 million a year prior.
- The company recorded net income of $7.5 million year-to-date in Q3 2025, reflecting collaboration activity, including the completion of a $150.0 million upfront payment under a 2024 Novartis license.
- In October 2023, Monte Rosa Therapeutics AG, a wholly-owned subsidiary, entered into a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche).
Capital Expenditures
- Monte Rosa Therapeutics, Inc. invested $651,000 in capital expenditures in Q3 2025, a 61.6% decrease from the previous quarter.
- For the last 12 months (ending around Q3 2025), capital expenditures were -$4.12 million.
- The company expects its capital expenditures to continue increasing.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 24.61 |
| Mkt Cap | 2.6 |
| Rev LTM | 62 |
| Op Inc LTM | -201 |
| FCF LTM | -170 |
| FCF 3Y Avg | -138 |
| CFO LTM | -169 |
| CFO 3Y Avg | -132 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -12.5% |
| Rev Chg 3Y Avg | 19.9% |
| Rev Chg Q | -40.6% |
| QoQ Delta Rev Chg LTM | -8.8% |
| Op Inc Chg LTM | -32.2% |
| Op Inc Chg 3Y Avg | -26.5% |
| Op Mgn LTM | -320.5% |
| Op Mgn 3Y Avg | -382.2% |
| QoQ Delta Op Mgn LTM | -52.1% |
| CFO/Rev LTM | -278.9% |
| CFO/Rev 3Y Avg | -295.6% |
| FCF/Rev LTM | -281.1% |
| FCF/Rev 3Y Avg | -297.8% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Developing a portfolio of novel and proprietary molecular glue degraders (MGDs) | 124 | 76 | 0 |
| Total | 124 | 76 | 0 |
| $ Mil | 2024 | 2023 |
|---|---|---|
| Developing a portfolio of novel and proprietary molecular glue degraders (MGDs) | -81 | -143 |
| Total | -81 | -143 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Developing a portfolio of novel and proprietary molecular glue degraders (MGDs) | -39 | -73 | -135 |
| Total | -39 | -73 | -135 |
| $ Mil | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Developing a portfolio of novel and proprietary molecular glue degraders (MGDs) | 304 | 342 | 366 | 49 |
| Total | 304 | 342 | 366 | 49 |
Price Behavior
| Market Price | $24.52 | |
| Market Cap ($ Bil) | 2.4 | |
| First Trading Date | 06/24/2021 | |
| Distance from 52W High | -3.1% | |
| 50 Days | 200 Days | |
| DMA Price | $19.25 | $16.87 |
| DMA Trend | up | up |
| Distance from DMA | 27.4% | 45.3% |
| 3M | 1YR | |
| Volatility | 56.3% | 93.6% |
| Downside Capture | 28.23 | 56.93 |
| Upside Capture | 138.24 | 225.83 |
| Correlation (SPY) | 20.4% | 16.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.67 | 0.92 | 1.02 | 0.78 | 1.18 | 1.42 |
| Up Beta | 2.38 | 2.37 | 1.59 | 1.52 | 2.42 | 1.33 |
| Down Beta | 0.60 | -0.16 | -0.56 | 0.77 | -0.53 | 0.83 |
| Up Capture | 156% | 172% | 189% | 102% | 462% | 1023% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 11 | 19 | 31 | 54 | 122 | 359 |
| Down Capture | -89% | 26% | 56% | 21% | 57% | 110% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 10 | 22 | 31 | 70 | 127 | 380 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GLUE | |
|---|---|---|---|---|
| GLUE | 387.6% | 93.5% | 2.06 | - |
| Sector ETF (XLV) | 21.8% | 15.7% | 1.06 | 14.8% |
| Equity (SPY) | 22.3% | 12.5% | 1.33 | 15.8% |
| Gold (GLD) | 24.4% | 27.8% | 0.77 | 7.7% |
| Commodities (DBC) | 23.6% | 18.7% | 1.00 | -6.9% |
| Real Estate (VNQ) | 13.2% | 13.9% | 0.65 | 4.9% |
| Bitcoin (BTCUSD) | -42.8% | 42.8% | -1.18 | 8.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GLUE | |
|---|---|---|---|---|
| GLUE | 0.6% | 100.6% | 0.43 | - |
| Sector ETF (XLV) | 6.8% | 14.9% | 0.27 | 23.9% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 27.4% |
| Gold (GLD) | 18.0% | 18.3% | 0.80 | 4.4% |
| Commodities (DBC) | 7.5% | 19.5% | 0.28 | -2.2% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.06 | 23.5% |
| Bitcoin (BTCUSD) | 12.3% | 53.5% | 0.42 | 17.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GLUE | |
|---|---|---|---|---|
| GLUE | 1.0% | 100.8% | 0.45 | - |
| Sector ETF (XLV) | 10.6% | 16.6% | 0.52 | 23.7% |
| Equity (SPY) | 15.8% | 17.9% | 0.75 | 27.3% |
| Gold (GLD) | 11.7% | 16.1% | 0.59 | 4.4% |
| Commodities (DBC) | 6.1% | 18.0% | 0.27 | -2.0% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.22 | 23.3% |
| Bitcoin (BTCUSD) | 58.0% | 66.2% | 0.98 | 17.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -2.8% | -7.0% | -19.7% |
| 3/17/2026 | -2.0% | -8.1% | 11.5% |
| 11/6/2025 | 5.7% | 15.0% | 45.0% |
| 8/7/2025 | -2.9% | 2.0% | 13.4% |
| 5/8/2025 | 9.6% | -3.9% | 30.1% |
| 3/20/2025 | 5.4% | -18.1% | -32.1% |
| 1/10/2025 | -4.8% | -3.8% | 7.7% |
| 11/7/2024 | 0.8% | -8.7% | -0.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 7 | 12 |
| # Negative | 10 | 12 | 7 |
| Median Positive | 5.3% | 7.2% | 12.2% |
| Median Negative | -3.4% | -5.9% | -19.7% |
| Max Positive | 9.6% | 21.8% | 45.0% |
| Max Negative | -16.0% | -18.1% | -32.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | -2.8% | -7.0% | -19.7% |
| 3/17/2026 | -2.0% | -8.1% | 11.5% |
| 11/6/2025 | 5.7% | 15.0% | 45.0% |
| 8/7/2025 | -2.9% | 2.0% | 13.4% |
| 5/8/2025 | 9.6% | -3.9% | 30.1% |
| 3/20/2025 | 5.4% | -18.1% | -32.1% |
| 1/10/2025 | -4.8% | -3.8% | 7.7% |
| 11/7/2024 | 0.8% | -8.7% | -0.4% |
| 5/9/2024 | -1.5% | -0.6% | -24.3% |
| 3/14/2024 | -8.4% | 12.0% | 8.4% |
| 11/9/2023 | -10.6% | -0.3% | 17.3% |
| 8/10/2023 | -1.6% | -4.7% | -12.1% |
| 5/11/2023 | 1.0% | -2.4% | 13.8% |
| 3/16/2023 | 7.4% | 7.2% | 4.9% |
| 11/10/2022 | 5.3% | 21.8% | 12.9% |
| 8/11/2022 | 5.2% | 3.6% | 4.0% |
| 5/11/2022 | -16.0% | -8.8% | -17.2% |
| 11/12/2021 | 2.3% | -13.8% | -28.3% |
| 8/12/2021 | -3.9% | 0.4% | 4.1% |
| SUMMARY STATS | |||
| # Positive | 9 | 7 | 12 |
| # Negative | 10 | 12 | 7 |
| Median Positive | 5.3% | 7.2% | 12.2% |
| Median Negative | -3.4% | -5.9% | -19.7% |
| Max Positive | 9.6% | 21.8% | 45.0% |
| Max Negative | -16.0% | -18.1% | -32.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/17/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/14/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/17/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/14/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/16/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/11/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/29/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 06/21/2021 | S-1/A |
Recent Forward Guidance
Updated 7/9/2026Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | Affirmed | Guidance: 0 for 2029 | |||||
Prior: Q4 2025 Earnings Reported 3/17/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2029 Cash Runway | Raised | Guidance: 2,028 for 2028 | |||||
Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2028 Cash Runway | 2,028 | ||||||
Insider Activity
Updated 7/7/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Townson, Sharon | Chief Scientific Officer | Direct | Sell | 7072026 | 23.31 | 6,000 | 139,849 | 1,581,345 | Form |
| 2 | Janku, Filip | Chief Medical Officer | Direct | Sell | 7012026 | 24.50 | 5,407 | 132,472 | 1,484,994 | Form |
| 3 | Janku, Filip | Chief Medical Officer | Direct | Sell | 6302026 | 22.95 | 6,000 | 137,700 | 1,376,816 | Form |
| 4 | Manning, Anthony M | Direct | Sell | 6302026 | 23.11 | 10,000 | Form | |||
| 5 | Janku, Filip | Chief Medical Officer | Direct | Sell | 6252026 | 21.42 | 30,000 | 642,681 | 1,285,191 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Townson, Sharon | Chief Scientific Officer | Direct | Sell | 7072026 | 23.31 | 6,000 | 139,849 | 1,581,345 | Form |
| 2 | Janku, Filip | Chief Medical Officer | Direct | Sell | 7012026 | 24.50 | 5,407 | 132,472 | 1,484,994 | Form |
| 3 | Janku, Filip | Chief Medical Officer | Direct | Sell | 6302026 | 22.95 | 6,000 | 137,700 | 1,376,816 | Form |
| 4 | Manning, Anthony M | Direct | Sell | 6302026 | 23.11 | 10,000 | Form | |||
| 5 | Janku, Filip | Chief Medical Officer | Direct | Sell | 6252026 | 21.42 | 30,000 | 642,681 | 1,285,191 | Form |
| 6 | Janku, Filip | Chief Medical Officer | Direct | Sell | 6252026 | 20.22 | 11,845 | 239,522 | 1,213,122 | Form |
| 7 | Champoux, Jennifer | Chief Operating Officer | Direct | Sell | 6252026 | 20.00 | 2,175 | 43,500 | 1,247,420 | Form |
| 8 | Townson, Sharon | Chief Scientific Officer | Direct | Sell | 6252026 | 20.00 | 3,000 | 60,000 | 1,356,900 | Form |
| 9 | Champoux, Jennifer | Chief Operating Officer | Direct | Sell | 6182026 | 19.00 | 2,176 | 41,344 | 1,185,049 | Form |
| 10 | Townson, Sharon | Chief Scientific Officer | Direct | Sell | 6182026 | 19.00 | 3,000 | 57,000 | 1,289,055 | Form |
| 11 | Warmuth, Markus | President & CEO | Direct | Sell | 6022026 | 19.44 | 5,466 | 106,253 | 11,557,166 | Form |
| 12 | Townson, Sharon | Chief Scientific Officer | Direct | Sell | 6012026 | 19.87 | 6,000 | 119,220 | 1,348,080 | Form |
| 13 | Champoux, Jennifer | Chief Operating Officer | Direct | Sell | 5282026 | 20.00 | 2,175 | 43,500 | 1,247,420 | Form |
| 14 | Champoux, Jennifer | Chief Operating Officer | Direct | Sell | 5262026 | 19.00 | 2,176 | 41,344 | 1,185,049 | Form |
| 15 | Manning, Anthony M | Direct | Sell | 5222026 | 18.01 | 10,000 | Form | |||
| 16 | Warmuth, Markus | President & CEO | Direct | Sell | 5052026 | 18.92 | 5,467 | 103,447 | 11,353,276 | Form |
| 17 | Warmuth, Markus | President & CEO | Direct | Sell | 4152026 | 17.64 | 8,000 | 141,125 | 10,680,872 | Form |
| 18 | Nickson, Philip | Chief Business & Legal Officer | Direct | Sell | 4102026 | 17.69 | 5,845 | 103,413 | 973,088 | Form |
| 19 | Warmuth, Markus | President & CEO | Direct | Sell | 3042026 | 17.92 | 5,466 | 97,974 | 10,996,038 | Form |
| 20 | Dunn, Edmund | Principal Accounting Officer | Direct | Sell | 3022026 | 17.50 | 536 | 9,380 | 397,128 | Form |
| 21 | Dunn, Edmund | Principal Accounting Officer | Direct | Sell | 3022026 | 18.10 | 25,164 | 455,506 | 410,777 | Form |
| 22 | Janku, Filip | Chief Medical Officer | Direct | Sell | 2242026 | 19.50 | 9,189 | 179,161 | 1,283,644 | Form |
| 23 | Warmuth, Markus | President & CEO | Direct | Sell | 1092026 | 23.49 | 5,466 | 128,373 | 14,536,138 | Form |
| 24 | Nickson, Philip | Chief Business & Legal Officer | Direct | Sell | 1052026 | 15.17 | 3,155 | 47,861 | 923,019 | Form |
| 25 | Champoux, Jennifer | Chief Operating Officer | Direct | Sell | 1052026 | 15.17 | 2,629 | 39,882 | 946,168 | Form |
| 26 | Dunn, Edmund | Principal Accounting Officer | Direct | Sell | 1052026 | 15.17 | 1,039 | 15,762 | 344,253 | Form |
| 27 | Warmuth, Markus | President & CEO | Direct | Sell | 1052026 | 15.17 | 10,135 | 153,748 | 9,472,194 | Form |
| 28 | Janku, Filip | Chief Medical Officer | Direct | Sell | 1052026 | 15.17 | 3,155 | 47,861 | 1,138,144 | Form |
| 29 | Townson, Sharon | Chief Scientific Officer | Direct | Sell | 1052026 | 15.17 | 3,155 | 47,861 | 1,029,209 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.